162 related articles for article (PubMed ID: 30340569)
21. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
[TBL] [Abstract][Full Text] [Related]
22. A meta-analysis of Prognostic factor of Pancreatic neuroendocrine neoplasms.
Gao Y; Gao H; Wang G; Yin L; Xu W; Peng Y; Wu J; Jiang K; Miao Y
Sci Rep; 2018 May; 8(1):7271. PubMed ID: 29739948
[TBL] [Abstract][Full Text] [Related]
23. Pancreatic neuroendocrine tumours: Grade is superior to T, N, or M status in predicting outcome and selecting patients for chemotherapy:A retrospective cohort study in the SEER database.
Zhai H; Li D; Feng Q; Qian X; Li L; Yao J
Int J Surg; 2019 Jun; 66():103-109. PubMed ID: 30872175
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis.
Oweira H; Petrausch U; Helbling D; Schmidt J; Mannhart M; Mehrabi A; Schöb O; Giryes A; Decker M; Abdel-Rahman O
World J Gastroenterol; 2017 Mar; 23(10):1872-1880. PubMed ID: 28348494
[TBL] [Abstract][Full Text] [Related]
25. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
[TBL] [Abstract][Full Text] [Related]
26. Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study.
Rindi G; Klersy C; Albarello L; Baudin E; Bianchi A; Buchler MW; Caplin M; Couvelard A; Cros J; de Herder WW; Delle Fave G; Doglioni C; Federspiel B; Fischer L; Fusai G; Gavazzi F; Hansen CP; Inzani F; Jann H; Komminoth P; Knigge UP; Landoni L; La Rosa S; Lawlor RT; Luong TV; Marinoni I; Panzuto F; Pape UF; Partelli S; Perren A; Rinzivillo M; Rubini C; Ruszniewski P; Scarpa A; Schmitt A; Schinzari G; Scoazec JY; Sessa F; Solcia E; Spaggiari P; Toumpanakis C; Vanoli A; Wiedenmann B; Zamboni G; Zandee WT; Zerbi A; Falconi M
Neuroendocrinology; 2018; 107(4):375-386. PubMed ID: 30300897
[TBL] [Abstract][Full Text] [Related]
27. Digestive Neuroendocrine Tumor Distribution and Characteristics According to the 2010 WHO Classification: a Single Institution Experience in Lebanon.
Kourie HR; Ghorra C; Rassy M; Kesserouani C; Kattan J
Asian Pac J Cancer Prev; 2016; 17(5):2679-81. PubMed ID: 27268650
[TBL] [Abstract][Full Text] [Related]
28. A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival.
Massironi S; Rossi RE; Zilli A; Casazza G; Ciafardini C; Conte D
Oncotarget; 2016 Apr; 7(14):18978-83. PubMed ID: 26959887
[TBL] [Abstract][Full Text] [Related]
29. Analysis of diagnosis and treatment for pancreatic neuroendocrine neoplasms: results of 47 cases in a single institution.
Lin XS; Zhu CL; Liu CH; Xie F; Zhou HC; Huang Q
Hepatogastroenterology; 2014; 61(136):2383-6. PubMed ID: 25699387
[TBL] [Abstract][Full Text] [Related]
30. Clinical Presentation and Diagnosis of Pancreatic Neuroendocrine Tumors.
Anderson CW; Bennett JJ
Surg Oncol Clin N Am; 2016 Apr; 25(2):363-74. PubMed ID: 27013370
[TBL] [Abstract][Full Text] [Related]
31. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.
Strosberg JR; Cheema A; Weber J; Han G; Coppola D; Kvols LK
J Clin Oncol; 2011 Aug; 29(22):3044-9. PubMed ID: 21709192
[TBL] [Abstract][Full Text] [Related]
32. Gender differences in pancreatic neuroendocrine neoplasms: A retrospective study based on the population of Hubei Province, China.
Fu M; Yu L; Yang L; Chen Y; Chen X; Hu Q; Sun H
Front Endocrinol (Lausanne); 2022; 13():885895. PubMed ID: 36004340
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
34. Gastroenteric neuroendocrine neoplasms classification: comparison of prognostic models.
Dolcetta-Capuzzo A; Villa V; Albarello L; Franchi GM; Gemma M; Scavini M; Di Palo S; Orsenigo E; Bosi E; Doglioni C; Manzoni MF
Cancer; 2013 Jan; 119(1):36-44. PubMed ID: 22744914
[TBL] [Abstract][Full Text] [Related]
35. Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes.
Cheng Y; Zhan H; Wang L; Xu J; Zhang G; Zhang Z; Hu S
Front Med; 2016 Dec; 10(4):444-450. PubMed ID: 27757796
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective.
Muscogiuri G; Altieri B; Albertelli M; Dotto A; Modica R; Barrea L; Fanciulli G; Feola T; Baldelli R; Ruggeri RM; Gallo M; Guarnotta V; Malandrino P; Messina E; Venneri MA; Giannetta E; Ferone D; Colao A; Faggiano A;
Endocrine; 2020 Aug; 69(2):441-450. PubMed ID: 32468269
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
38. Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis.
Kamarajah SK; Burns WR; Frankel TL; Cho CS; Nathan H
Ann Surg Oncol; 2017 Jul; 24(7):2023-2030. PubMed ID: 28213792
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
[TBL] [Abstract][Full Text] [Related]
40. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors.
Bilimoria KY; Bentrem DJ; Merkow RP; Tomlinson JS; Stewart AK; Ko CY; Talamonti MS
J Am Coll Surg; 2007 Oct; 205(4):558-63. PubMed ID: 17903729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
